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Abstract
Background: The human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) immune response is one of the
major factors determining the genetic diversity of human immunodeficiency virus (HIV). There are few population-based
analyses of the amino acid variations associated with the host HLA type and their clinical relevance for the Asian population.
Here, we identified HLA-associated polymorphisms in the HIV-1 CRF01_AE Gag protein in infected married couples, and
examined the consequences of these HLA-selected mutations after transmission to HLA-unmatched recipients.
Methodology/Principal Findings: One hundred sixteen HIV-1-infected couples were recruited at a government hospital in
northern Thailand. The 1.7-kb gag gene was amplified and directly sequenced. We identified 56 associations between amino
acid variations in Gag and HLA alleles. Of those amino acid variations, 35 (62.5%) were located within or adjacent to regions
reported to be HIV-specific CTL epitopes restricted by the relevant HLA. Interestingly, a significant number of HLA-
associated amino acid variations appear to be unique to the CRF01_AE-infected Thai population. Variations in the capsid
protein (p24) had the strongest associations with the viral load and CD4 cell count. The mutation and reversion rates after
transmission to a host with a different HLA environment varied considerably. The p24 T242N variant escape from B57/58
CTL had a significant impact on the HIV-1 viral load of CRF01_AE-infected patients.
Conclusions/Significance: HLA-associated amino acid mutations and the CTL selection pressures on the p24 antigen appear
to have the most significant impact on HIV replication in a CRF01_AE-infected Asian population. HLA-associated mutations
with a low reversion rate accumulated as a footprint in this Thai population. The novel HLA-associated mutations identified
in this study encourage us to acquire more extensive information about the viral dynamics of HLA-associated amino acid
polymorphisms in a given population as effective CTL vaccine targets.
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Introduction
Accumulating evidence indicates that cytotoxic T lymphocytes
(CTLs) play a central role in controlling human immunodeficiency
virus (HIV) replication in vivo, and a number of CTL-inducing
vaccines have been developed [1,2]. All trials of CTL-inducing
vaccines against HIV have been unsatisfactory including the most
recent trial conducted in Thailand [3,4,5]. Genetic polymorphisms
in the human leukocyte antigens (HLAs) are key factors
contributing to the complexity of developing CTL-inducing
vaccines [6,7]. HLA class I molecules play a critical role in
defining the epitopes of CTLs, which probably influence their
antiviral efficacy. The extraordinary capacity of this virus to
generate genetic diversity is another important factor contributing
to this complexity. To date, 13 prototype HIV clades and 43
circulating recombinant forms have been described worldwide and
HIV diversity appears to be increasing as the infection spreads [8].
Once the virus infects a host, it rapidly evolves and evades the
host cellular immune response. Viral adaptation to the HLA-
restricted immune response and the selection of viral mutations
associated with the loss of the antiviral immune response have
been described in both acute and chronic HIV-1 infections at the
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also been reported at the population level [11,12]. Therefore,
there is a growing concern that HIV may evolve to reduce the
availability of key CTL epitopes that are associated with the
control of HIV infection at the population level. This in turn
would greatly affect the clinical outcomes of HIV/AIDS.
Therefore, these associations are becoming increasingly important
for effective CTL-based vaccine strategies.
Several studies have attempted to define HLA-associated
mutations in a given population using a large number of HIV
genome sequences and to determine their influence on clinical
outcomes [13,14]. These studies have identified HLA polymor-
phisms in the HIV-1 Gag protein and this association continues to
be reinforced [15]. However, most information has been derived
from studies of subtype-B-HIV-infected Caucasian and subtype-C-
HIV-infected African populations, and very little information is
available on the CRF01_AE virus, the predominant clade
circulating in southeast Asia [16,17].
Therefore, in this study, we investigated the amino acid
variations in the HIV-1 CRF01_AE Gag protein among HIV-1-
infected people with known HLA alleles in Thailand, with the
primary objective of identifying the amino acid mutations
associated with the host HLA class I types and their influence
on clinical outcomes. Moreover, because our cohort included
dozens of discordant couples (viral transmission pairs), we took
advantage of this point and further analyzed the fate of these
HLA-selected mutations after transmission to HLA-unmatched
recipients.
Methods
Ethical statement
This study was approved by the Ethics Committee of the Thai
Ministry of Public Health and was conducted in accordance with
the set guidelines for research. All patients provided their written
informed consent for the collection of the samples and their
subsequent analysis.
Population and samples
We recruited 116 chronically HIV-1-infected Thai couples (219
patients in total) at a government referral hospital in northern
Thailand between 6 July 2000 and 15 October 2002. The cohort
has been described in detail elsewhere [18]. We obtained two
sequential blood samples from each patient, with an interval of 6–
27 months (mean interval 19.75 months, mode 24 months)
between the two collections. The majority of patients were naı ¨ve
to antiretroviral therapy, except for 27 individuals who were
receiving treatment with single or dual nucleoside reverse
transcriptase inhibitors. However, no patient was receiving highly
active antiretroviral therapy. The median (interquartile range,
IQR) CD4
+ cell count in our study population was 163 (23, 370)
cells/mL, and the median (IQR) plasma viral load was 5.20 (4.54,
5.63) log10 RNA copies/mL. Peripheral blood mononuclear cells
(PBMCs) were separated with a commercially available cell-
separation tube (CPTH Cell Preparation Tube with Sodium
Citrate, BD, Franklin Lakes, NJ, USA) and used in this study.
HLA class I typing
Genomic DNA was extracted from patient PBMCs with the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), according to
the manufacturer’s instructions. HLA class I typing for the A and
B loci was performed using a PCR microtiter plate hybridization
method (WAKFlowH HLA typing kit) (Wakunaga Co. Ltd.,
Hiroshima, Japan), according to the manufacturer’s instructions.
For statistical analysis, each HLA allele of each individual was
assigned a two-digit designation.
PCR amplification of HIV gag and sequencing
Genomic DNA was extracted from patient PBMCs as described
above, and nested PCR was performed. First, the 9.1-kb nearly
full-length HIV genome was amplified using Takara LA Taq DNA
polymerase (Takara, Shiga, Japan) and the following primers,
which bind to both the long terminal repeat (LTR) regions of the
HIV genome: sense outer primer, MSF12b 59-AAATCTCTAG-
CAGTGGCGCCCGAACAG-39, and antisense outer primer,
OFMR1 59-TGAGGGATCTCTAGTTACCAGAGTC-39. The
PCR conditions were as follows: melting at 95uC for 5 min; 30
cycles each of 95uC for 10 s, 65uC for 30 s, and 68uC for 8 min;
and a final extension at 68uC for 7 min. The 1.7-kb fragment
containing the entire gag gene was amplified from the first round
PCR product using Qiagen Taq DNA polymerase (Qiagen): sense
inner primer, Gag-F1 59-TCTCGACGCAGGACTCGGCTT-
GCT-39, and antisense inner primer, Gag-R2 59-CCTCCAATT-
CCCCCTATCATTTTTGG-39. The thermocycling conditions
for the second round of PCR were as follows: melting at 95uC for
2 min; 30 cycles each of 95uC for 30 s, 60uC for 30 s, and 68uC for
90 s; anda final extensionat 68uC for7 min. ThePCRproductwas
analyzed by gel electrophoresis. The appropriate PCR products
were directly sequenced by Macrogen Inc., Korea.
Sequence analysis
The HIV nucleic acid sequences were analyzed to identify their
subtypes, using the RIP 2.0 software (http://www.hiv.lanl.gov/
content/sequence/RIP/RIP.html). All CRF01_AE sequences
were submitted to GenBank (accession number GU458430–
GU458799). Only the sequences that included the complete gag
open reading frame were selected for sequence analysis. The
sequences were aligned and translated using the MEGA 3.1
software [19]. A consensus sequence was created from the most
abundant amino acid at each position in the cohort. HIV
transmission between spouses was confirmed by constructing a
neighbor-joining phylogenetic tree using the entire gag nucleotide
sequences derived from the whole sample. If the viruses derived
from a husband and wife clustered on the same branch, the
couple’s viruses were regarded as having a common ancestor,
implying that the virus was transmitted between them. On this
basis, we identified 68 such couples. Each member of the
remaining couples was considered to be infected with virus distinct
from that infecting his/her spouse. The direction of transmission
was determined by in-depth interviews with field workers. The
associations between the sequence polymorphisms and the HLA
types were analyzed with Fisher’s exact test with a 95% confidence
interval (CI), using only the patients who were source of virus in
the couples (index cases), and was limited to the HLA alleles
shared by at least five subjects to ensure sufficient statistical power.
Amino acids that were identical to the consensus sequence were
considered to be ‘‘dominant’’ amino acids, and any difference
from the consensus sequence was classified as ‘‘non-dominant’’.
An amino acid position was declared an ‘‘HLA-associated variable
site’’ if a significant HLA association was identified in the sequence
at both times of sample collection. The HLA-associated variable
site was mapped in relation to the best-defined CTL epitopes
published in the Los Alamos HIV Databases [http://www.hiv.
lanl.gov/content/sequence/HIV/mainpage.html, accessed Dec.
2009].
For detecting adaptive evolution in protein-coding sequences
under natural selection in the population, the branch lengths and
nucleotide substitution rate parameter was estimated to approx-
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codon model, which estimates synonymous and non-synonymous
rate independently for every amino-acid, was performed. The
estimating site-by-site variation rate was evaluated by single
likelihood ancestor counting (SLAC) and fixed-effected likelihood
(FEL) methods. The adaptive evolution study was done by HyPhy
2.0 software [20,21].
Statistical analysis
All statistical analyses were performed with Excel 2007. Fisher’s
exact test with a 95% CI was used to detect HLA-associated
dominant or non-dominant sites, and Spearman’s correlation test
was used to determine the number of HLA-associated non-
dominant sites and for the viral load correlation analysis. We also
used one-way ANOVA to test the differences in viral load among
the T242X mutations with or without compensatory mutations in
the HLA_B*57/*58-positive or -negative groups.
Results
Sequencing results, study population, and HLA allele
frequencies
By subtype analysis, nine individuals were found to be infected
with subtype B or a CRF01_AE/subtype B recombinant form of
virus, so they were excluded from further analysis. Then, 370
CRF01_AE Gag sequences were determined in the 209 and 161
samples at the first and second time points, respectively, obtained
from 219 individuals (116 couples). The numbers of CRF01_AE-
infected individuals carrying specific HLA class I alleles are shown
in Figure 1. The most frequent HLA_A allele was A*11, followed
by A*02, A*24, and A*33. The allele B*15 was the most frequent
HLA_B allele, followed by B*40, B*46, and B*13. Clearly, the
HLA distribution in Thailand differs from those in North
American and African countries. We also analyzed the linkage
disequilibrium. Strong linkage was found between A*33 and B*58
(p=1.39610
212), as previously reported elsewhere [22,23].
HLA-associated amino acid variations
To identify HLA-associated amino acid variations, we analyzed
the Gag amino acid sequences in relation to the HLA types.
Phylogenetic analysis identified 68 couples in which the
CRF01_AE virus transmission between the spouses was confirmed
(Figure S1). In the remaining couples, the spouses were considered
to be infected with distinct viruses. To minimize the lineage effect
that might result from sampling viruses from concordant couples,
we included only one spouse from each couple in the analysis.
After removing the contact cases from these 68 concordant
couples, 144 first samples and 122 second samples were used for
further analysis. We found 44 amino acid site variations (among
the known 498 amino acid positions) in the Gag region. All these
Figure 1. HLA_A and HLA_B allele distributions among patients. HLA allele distributions: the frequencies of HLA_A and _B alleles occurring in
at least five or more individuals are shown in (A) and (B), respectively. The number of HLA-associated amino acid variations is indicated in brackets
under each HLA allele.
doi:10.1371/journal.pone.0011179.g001
CRF01_AE Gag Sequences and HLA
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11179variations showed statistically significant associations with some of
the HLA types (p,0.05) and these are described below.
In total, 56 associations between the HLA types and amino acid
variations were identified: 20 associations with five HLA_A alleles
(A*02, *11, *24, *31, and *33) and 36 associations with 15 HLA_B
alleles (all except B*15 and *51). Seventeen positions (23
associations) were in p17, 16 positions (21 associations) in p24,
and the remaining 11 positions (12 associations) were in p2/7/1/6
(Table 1). The associations in p17 were restricted more by HLA_A
alleles (13/23 associations), whereas the associations in p24 were
restricted more by HLA_B alleles (16/21 associations).
The number of HLA-associated amino acid variations did not
necessarily correlate with the frequency of the allele. More than
five amino acid variations were associated with B*58 and B*52,
despite the relative infrequency of these alleles, whereas no
variation was significantly associated with one of the most frequent
alleles, B*15 (Figure 1B). Among the 56 HLA-associated amino
acid variations, 49 (87.5%) were selected by non-dominant amino
acids in the presence of the specific HLA type. The remaining
seven (12.5%) variations were selected by dominant amino acids in
the presence of a specific HLA type. Six amino acid variations
caused by negative selection were located in p17, whereas only one
was located in p24. Dominant amino acid selection was always
associated with frequent HLA alleles: five variations were
associated with A alleles (A*11, A*02, A*24, or A*33) and two
were associated with B alleles (B*46 or B*27).
We also found that 35 (62.5%) HLA-associated amino acid
variations were located within or adjacent to the best-defined
HIV-specific CTL epitopes, restricted by the relevant HLA allele
[24] (Table 1). Some HLA-associated amino acid variations were
located at anchor positions of binding peptides: A*24-associated
F79X, B*40-associated E93X, and B*58-associated V485X
(Table 1). Odds ratios were widely variable, ranging from 2.60
to 90.0, with a median (IQR) of 7.87 (4.48, 13.3). The odds ratio
was highest by far at B*58-associated T242.
The codon-based analysis revealed a large number of significant
selection sties in the Gag protein, mostly purifying selection;
among the 498 Gag amino acid positions, 270 (54.2%) sites and 52
(10.4%) sites were identified by either SLAC or FEL method as
purifying selection and positive selection sites, respectively (Table
S1). Interestingly 19 (36.5%) out of the 52 positive selection sites
located at the sites of HLA-associated amino acid variations,
whereas only 6 (2.2%) out of 270 purifying selection sites located at
the sites of HLA-associated amino acid variations (Table 1). This
implies that HLA-pressure is one of major factors driving the
positive amino acid selection among Gag protein.
Associations between numbers of HLA-associated amino
acid variants and clinical outcomes
After defining the HLA-associated amino acid variation sites in
CRF01_AE in the analysis described above, we counted the
numbers of HLA-associated variations in autologous viral
sequences for each patient, and plotted them on the X axis, and
plotted the plasma viral loads and CD4
+ cell counts on the Y axis.
We found significant associations between the numbers of HLA-
associated amino acid variations and the CD4
+ cell counts or viral
loads. Patients with a higher number of HLA-associated amino
acid variants tended to have a higher plasma viral load and lower
CD4
+ cell counts (Figure 2A). We further analyzed these
associations according to the subregions of Gag in which the
variations occurred. Intriguingly, these correlations were mainly
driven by the associations with variations in the p24 region
(Figure 2B).
Amino acid variations in a recipient host with different
HLA alleles
With in-depth interviews conducted by designated field workers,
the index and contact cases were determined among the 65
concordant couples. Looking at the viral sequences in a pairwise
manner, we noted that the frequencies of de novo HLA-associated
mutations and reversions after viral transmission to contact cases
with distinct HLA profile varied considerably, depending on the
amino acid positions involved. Mutations and reversions of each
HLA-associated amino acid variant were studied whenever data
for at least five couples were available. When the virus was
transmitted to a contact case with a different HLA environment, as
confirmed by sequencing, the rate of reversion or mutation for
each HLA-associated amino acid variant was calculated and was
plotted on a scatter graph (Figure 3). To avoid overestimation of
the mutation or reversion rate, we counted only HLA-associated
sites with p values of ,0.01 with a 99% CI and with a
denominator of more than one when we calculated their rates.
In total, 30 HLA-associated amino acid variation sites were listed.
For instance, at the S9X site restricted by B*13, which was selected
by non-dominant amino acid, the mutation rate was calculated as
5/11 (=0.45), five S9T–B*13-positive contact cases divided by 11
S9S–B*13-negative index cases. Its reversion rate was calculated as
4/6 (=0.67), four S9S–B*13-negative contact cases divided by six
S9T–B*13-positive index cases (see supplementary data for details
of the mutation and reversion sequence variations, Table S2). For
dominant amino acid selection sites, the mutation rate and
reversion rate were calculated in the opposite way. At the K76X
site restricted by A*02, the mutation rate was calculated as 3/3
(=1.0), three K76K–A*02-positive contact cases divided by three
K76R–A*02-negative index cases. The reversion rate was
calculated as 1/13 (=0.077), one K76R–A*02-negative contact
case divided by 13 K76K–A*02-positive index cases. The average
reversion rate was 0.42 and the average mutation rate was 0.33.
There was a rough inverse relationship between the reversion and
mutation rates. P255X (A*11) and I223X (B*13) scored reversion
rates of 1.00 and both had low mutation rates. Conversely, F79X
(A*24), K76X (A*02), and T242X (B*58) had mutation rates of
1.00 and the former two had low reversion rates. Interestingly,
T242X (B*58) was outstanding in that both its mutation rate and
reversion rate were very high. This indicates that the rate of
accumulation of CTL escape mutations in a given population
varies considerably among mutations and restricting HLA types.
T242N mutations
As described above, T242X had a high reversion rate. The vast
majority of T242X mutations were T242N, known as an escape
mutation from CTL (TSTLQEQIGW: TW10), restricted by the
protective HLA alleles B*57 and B*5801 in the setting of clade B
and C infections. This mutation emerges almost universally in
B*57/*5801-positive subjects. Several studies have demonstrated
that the T242N substitution affects viral replicative fitness in vitro
and it is believed to contribute to the protective effect of these
alleles against the progression of HIV disease [25,26]. Moreover,
several mutations within the cyclophilin A binding loop, such as
H219 and M228, have been shown to compensate to some extent
for the reduced viral replicative capacity caused by T242N
[27,28]. However, the roles of T242N and the compensatory
mutations in CRF01_AE infections are unknown. HLA_B*5801 is
known to present the same epitopes as B*57 [29], and our
unpublished data indicate that the vast majority of B*58 alleles in
Thailand are B*5801. There were no statistically significant
differences in the plasma virus loads of the B*57/*58-positive and -
negative populations in our cohort (data not shown). Five of the 23
CRF01_AE Gag Sequences and HLA
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Part Position Selection*
Restricted
HLA HLA non-dominant dominant
Odds
rario
95% CI
range p value(Fisher) Reported CTL epitope
p17 V7X Pos B*44 + 5 6 5.69 1.56 0.0132
2 17 116 20.69
S9X n.s B*13 + 12 7 22.10 6.98 8.98E-08
2 9 116 69.98
K18X n.s A*33 + 1 36 0.10 0.01 0.00488
2 24 83 0.74
R30X Pos A*11 + 52 36 2.60 1.30 0.010045622 (Flanking) KIRLRPGGK
2 20 36 5.20
A*24 + 10 35 0.17 0.08 1.10356E-05 A*2402: KYKLKHIVW
2 62 37 0.38
V35X n.s B*52 + 2 13 19.69 1.67 0.0282
2 1 128 232.20
T53X Pos A*02 + 16 51 4.52 1.56 0.004090448 A2: GLLESSEGC
2 5 72 13.12
A54X Pos A*02 + 12 55 8.18 1.76 0.00332653 A2: GLLESSEGC
2 2 75 38.05
S66X Pos B*18 + 4 1 28.71 3.03 0.001572746
2 17 122 272.17
L75X Pos A*33 + 7 30 3.33 1.08 0.04825
2 7 100 10.26
B*57 + 2 1 21.50 1.81 0.02502 (Flanking) B57: RSLYNTVATLY
2 12 129 254.77
B*58 + 7 13 9.00 2.73 0.000653882 (Flanking) B58: RSLYNTVATLY
2 7 117 29.71
K76X Pos A*02 + 7 60 0.33 0.13 0.01934 (Flanking) A*02: SLYNTVATL
2 20 57 0.85
F79X Pos A*24 + 6 39 0.25 0.10 0.003083254 (Flanking) A24: LYNTVATL
2 38 61 0.64
T81X Pos B*58 + 8 12 4.84 1.70 0.004583808 B58: RSLYNTVATLY
2 15 109 13.77
V82X Pos A*24 + 24 21 4.51 2.10 0.000153966 (Flanking) A24: LYNTVATL
2 20 79 9.69
B*58 + 11 9 3.37 1.28 0.0171 B58: RSLYNTVATLY
2 33 91 8.86
V83X Pos A*11 + 22 66 0.09 0.04 2.48E-10 IATLWCVHQR
2 44 12 0.20
A*24 + 30 15 3.50 1.67 0.001063416 A24: LYNTVATL
2 36 63 7.36
E93X n.s B*40 + 21 14 13.36 5.33 8.96E-09 B*4001: IEIKDTKEAL
2 11 98 33.52
I104X Pos A*11 + 64 24 4.44 2.17 5.18849E-05 A11: KIEEEQNKSK
2 21 35 9.10
B*27 + 4 9 0.27 0.08 0.0392
2 81 50 0.94
S125X n.s A*11 + 15 73 3.63 1.00 0.0419
2 3 53 13.18
p24 M186X Purify B*35 + 1 4 0.0347
2 01 3 9
A196X n.s B*38 + 4 13 38.77 4.03 0.000641253 B38: GHQAAMQML
CRF01_AE Gag Sequences and HLA
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Restricted
HLA HLA non-dominant dominant
Odds
rario
95% CI
range p value(Fisher) Reported CTL epitope
2 1 126 373.21
E203X n.s B*52 + 4 11 6.34 1.60 0.01658 (Flanking) B52: HQAAMQMLK
2 7 122 25.06
I223X n.s B*13 + 4 15 6.40 1.55 0.0181 (Flanking) B13: GQMREPRGSDI
2 5 120 26.48
M228X n.s B*13 + 9 10 5.35 1.91 0.002052971 B13: GQMREPRGSDI
2 18 107 14.98
T242X Pos A*33 + 14 23 12.42 4.06 2.88923E-06
2 5 102 37.94
B*46 + 0 34 0.00 0.007061705
2 19 91
B*57 + 3 0 0.001988329 B*5701, 5703: TSTLQEQIGW
2 16 125
B*58 + 15 5 90.00 21.75 6.06E-13 B*5801: TSTLQEQIGW
2 4 120 372.40
G248X n.s A*33 + 8 29 3.94 1.32 0.0238
2 7 100 11.78
B*58 + 8 12 11.14 21.75 0.000120432 B*5801: TSTLQEQIGW
2 7 117 372.40
P255X Pos A*11 + 20 68 7.94 1.78 0.001603328
2 2 54 35.48
V280X Pos B*46 + 12 22 14.45 4.26 4.9055E-06
2 4 106 49.02
S281X n.s B*52 + 10 5 21.45 6.22 9.32E-07 B*5201: RMYSPTSI
2 11 118 74.04
R286X n.s B*52 + 7 8 13.23 3.82 0.000122838 (Flanking)B*5201: RMYSPTSI
2 8 121 45.79
D295X Purify B*39 + 2 7 38.29 3.09 0.010144785
2 1 134 474.84
T310X n.s A*33 + 13 24 3.92 1.61 0.005101645 A*33 motif: VDRFYKLTRAEQAS
2 13 94 9.54
B*58 + 8 12 3.93 1.41 0.011165919 B*5801: QATQDVKNW
2 18 106 10.94
N315X Purify A*33 + 8 29 5.63 1.71 0.004581687 (Flanking)A*33:
VDRFYKLTRAEQAS
2 5 102 18.52
T348X n.s B*35 + 1 4 0.0347
2 01 3 9
S357X Purify B*07 + 2 8 10.92 1.59 0.039 B*0702: GPSHKARVL
2 3 131 74.94
p2 R387X Pos A*31 + 4 2 8.22 1.43 0.0197
2 27 111 47.26
B*27 + 6 7 3.63 1.12 0.0345
2 25 106 11.76
p7 HXB2
R403X
Pos A*31 + 2 4 16.75 2.34 0.020250589 A*3101: LARNCRAPRK
(R401X) 2 4 134 119.78
p6 HXB2
P453X
Pos B*55 + 6 3 18.77 4.19 0.000158687
(P451X) 2 13 122 84.06
Table 1. Cont.
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statistically significant difference in their plasma viral loads or CD4
cell counts, i.e., in terms of the presence or absence of T242X in
these patients (data not shown). We then stratified the B57*/*58-
positive patients with T242X according to the presence/absence
of the described compensatory mutations. Interestingly, we found
that B*57/*58-positive patients with the compensatory mutations
had significantly higher viral loads and lower CD4 cell counts than
those without the compensatory mutations (Figure 3), indicating
that the proposed mechanism of virus attenuation by the escape
mutation and its restoration by the compensatory mutations at the
B*57/*5801 TW10 epitope is applicable in the context of
CRF01_AE infections.
T242N mutations and transmission
It was recently reported that the transmission of viruses with
attenuating CTL escape mutations, particularly T242N from
B*57-restricted CTL, is associated with better early clinical
outcomes in HLA-unmatched recipients [30,31]. However, the
long-term effects of the transmission of these viruses to HLA-
unmatched recipients remain unknown. We summarized the
amino acid variations around the TW10 epitope in B*57/*58-
negative contact cases who had contracted the virus from B*57/
*58-positive spouses and their clinical features (Table 2). Only two
B*57/*58-negative spouses carried the T242N mutation at the
time of sampling. Both had very high CD4 cell counts of .500
cell/mL and very low viral loads of less than 10
4 copies/mL, which
is in distinct contrast to the remaining six B*57/*58-negative
spouses who lacked T242N (median plasma viral load, 5.39 log
copies/mL), and supports the results of the recent study by
Chopera et al. [28]. However, because the T242N escape
mutation is known to emerge within the first three months of
infection in B*57-positive subjects [32], it is unlikely that these six
contact cases had acquired the wild-type T242 virus, but instead,
the transmitted T242N probably reverted after its transmission to
these recipients. These data suggest that the majority of the
recipients from B*57/*58-positive donors do not receive the
benefit conferred by the transmission of the attenuated virus after
many years of infection, although we did not know the duration of
the infection in each patient in the present study. We identified
three other patients without the B*57/B*58 alleles who carried
viruses with T242N, and they all had very low viral loads of less
than 10
4 copies/mL (data not shown). We presume that they
contracted the virus from B*57/B*58-positive patients, although
we could not identify their index cases in our study population.
Taken together, these results imply that the transmission of CTL-
selected attenuated viruses might confer a survival advantage on
HLA-unmatched recipients, at least during the early stage of
infection, and that this advantage is not limited to infection with a
particular clade of virus. However, this effect may not be retained
for an extended period of time.
Discussion
This is the first published study that systematically analyzes
variations in the Gag sequence and their associations with HLA
in HIV-1 CRF01_AE infections. We identified 56 amino acid
variations at 44 amino acid positions, which were significantly
associated with a particular HLA class I type. We found that a
substantial number of HLA-associated amino acid variations
appeared to be unique to this CRF01_AE-infected Thai
population. However, despite these distinct variants, we con-
firmed that the capsid protein (p24) is probably the preferred
target of CTLs in CRF01_AE infections. We also found that the
Part Position Selection*
Restricted
HLA HLA non-dominant dominant
Odds
rario
95% CI
range p value(Fisher) Reported CTL epitope
HXB2
T456X
Pos B*56 + 5 3 5.89 1.33 0.02086
(T454X) 2 30 106 26.07
M463X n.s B*27 + 6 7 5.38 1.62 0.008955598
2 18 113 17.84
HXB2
Q476X
n.s B*52 + 4 11 15.27 3.03 0.002287463
(Q473X) 2 3 126 77.09
HXB2
E480X
Purify B*40 + 11 24 7.87 2.65 0.000183624 B*4001: KELYPLTSL
(E479X) 2 6 103 23.39
HXB2
L483X
n.s B*40 + 22 13 4.90 2.18 0.000166254 B*4001: KELYPLTSL
(H480X) 2 28 81 11.00
HXB2 485Xn.s B*40 + 7 28 3.64 1.18 0.0424 B*4001: KELYPLTSL
(P482X) 2 7 102 11.25
HXB2 485XPurify B*40 + 7 28 3.64 1.18 0.008631568 B*4001: KELYPLTSL
(P483X) 2 7 102 11.25
HXB2
T487X
n.s B*58 + 7 13 6.88 2.20 0.0018202 B58: LASLRSLF
(V485X) 2 9 115 21.56
Foot note for Table 1: *Pos. positive selection, n.s. not significant; P483X was an insertion mutation.
doi:10.1371/journal.pone.0011179.t001
Table 1. Cont.
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transmission to HLA-unmatched recipients varies considerably,
suggesting that the rate of accumulation of CTL escape mutations
in a given population differs substantially between mutations.
Our data also suggest that the transmission of CTL-selected
attenuated viruses is likely to confer a survival benefit on
HLA-unmatched recipients, at least during the early days of the
infection.
These associations between HLA and viral sequences can be
explained in several ways. The majority of associations are
probably attributable to specific mechanisms by which the virus
escapes from HLA-restricted, HIV-specific CTLs, such as loss of
Figure 2. Associations between numbers of HLA-associated mutation sites and CD4 cell count or viral load. A regression line is drawn
in each graph: (A) shows the relationships with HLA-associated amino acid variations in the whole Gag sequence, and (B) shows the relationships with
amino acid variations in p17, p24, and p2/p7/p1/p6.
doi:10.1371/journal.pone.0011179.g002
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changes in peptide processing and presentation [1]. In fact, we
found that two thirds of the HLA-associated variations were
located within known CTL epitopes or their flanking regions.
However, most previously reported CTL epitopes were identified
in studies of other clades, indicating that these CTLs are probably
cross-clade CTLs. Because studies of CTL epitopes in CRF01_AE
infections are limited, we believe that several other mutations may
occur in clade-specific CTL epitopes that have not yet been
reported. Our current work on CTL epitope mapping using
overlapping CRF01_AE Gag peptides has identified several new
CTL epitopes, and at least two amino acid mutations have been
found within the newly identified CRF01_AE Gag CTL epitopes
(data are in preparation). Linkage disequilibrium can also explain
the associations between HLA and viral sequences. There is a
strong association between HLA_A*33 and _B*58 [22,23]. The
A*33-associated T242X and G248X mutations are widely known
to be selected by HLA_B*57/*5801 [26], so they are likely to be
reflected in the linkage disequilibrium with B*58. Some HLA-
associated mutations may also be part of the structural and
functional compensatory mechanism underlying the development
of primary CTL escape mutations, which can arise at sites
considerably remote from the relevant epitopes [30].
This study has relatively low statistical power compared with
previous studies. However, one of its strong aspects is that we
identified a substantial number of HLA-associated amino acid
variations that appear to be unique to a CRF01_AE-infected Thai
population. Many of these variations do not appear in the list of
HLA-associated mutations identified in subtype-B infections in
over 1,500 subjects [15], and this cannot be explained by the
relatively low statistical power of the present study. For instance,
mutations such as S9X, V280X, and P453X had convincingly
strong associations with HLA_B*13, _B*46, and _B*55, respec-
tively (p,0.001; Table 1). However, none of these associations
have been noted in subtype B, suggesting that there are a number
of unidentified CTL pressures on Gag in the context of
CRF01_AE infections in the Asian population. This indicates
that an extensive search for CTL epitopes in various clades is
warranted to facilitate the development of globally effective CTL
vaccines.
Several publications have suggested that the Gag CTL response,
as measured by interferon c ELISPOT, has the most profound
effect on the clinical outcome in subtype B and subtype C
infections. Responses to the capsid protein are also likely to be
most crucial in the containment of viral replication in vivo [31]. In
this study, we have shown that variations in the capsid protein
(p24) had the strongest association with viral load and CD4 cell
count, indicating that regardless of the HIV clade, the p24 capsid
is the most preferred target of HIV-1-specific CTLs. Therefore,
p24 may be one of the important targets for effective CTL-based
vaccines.
Reversion rates and mutation rates
When the virus is transmitted into a new host with a different
HLA environment, the virus, which had already adapted to the
previous host, must adapt again to the new HLA environment by
reversion of the previous mutations and/or the creation of new
mutations. One of the most interesting results of the present study
is the variability in the reversion and mutation rates for each HLA-
associated variant. We found that these rates varied considerably,
depending upon the amino acid position, and that the reversion
rate tended to correlate inversely with the mutation rate. It is
plausible that an amino acid change with a low reversion rate
tends to accumulate in the population, and that the rate of
accumulation is higher if the mutation rate is higher and especially
if its HLA allele is dominant. In fact, we found that all the
Figure 3. Rates of reversion and mutation for each HLA-associated amino acid variant. HLA-associated mutation and reversion rates after
viral transmission to contact spouses with distinct HLA profiles were calculated and plotted. Amino acid variations selected by non-dominant amino
acid (N) and dominant amino acid (&) are shown.
doi:10.1371/journal.pone.0011179.g003
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common HLA alleles and rarely changed from the consensus
sequence, even after they were transmitted to HLA-unmatched
recipients. These findings suggest that the viruses circulating
within the population had already adapted to the common HLA
alleles, resulting in best-fit sequences that could escape from those
alleles. The results of our study will increase our understanding of
the influence of immune pressure on HIV and on the future
direction of virus evolution. Conversely, it is also plausible that an
amino acid change with a high reversion rate, presumably with a
functional or structural constraint at that position, is unlikely to
accumulate rapidly in the population. It will be important for
future CTL vaccine development to consider whether an escape
mutant will accumulate or not. Therefore, further studies of this
kind are required to provide valuable insights for future vaccine
design.
T242N issues
This is the first report indicating that the p24 T242N escape
mutation from the B*57/*58 CTL has a significant impact on the
HIV-1 viral load in CRF01_AE infections and that the mutations,
H219 and M228, compensate for the crippling effect of T242N.
Although this is a rather predictable result because the TW10 site
is conserved throughout the HIV-1 clades, it increases our insight.
Two other dominant CTL epitopes within the capsid protein are
restricted by B*57 (IW9: ISPRTLNAW; KF11: KAFSPEVIPMF).
However, the founder virus of CRF01_AE has a well-described
‘peptide-processing mutation’ at IW9 that affects the epitope
presentation on HLA class I molecules, and a well-described CTL
escape mutation within KF11 [33]. In fact, 100% of the
CRF01_AE sequences in our cohort carried these amino acid
substitutions (data not shown; see the Methods, for the GenBank
accession number), indicating that these two CTL epitopes are less
likely recognized in CRF01_AE infections. Several lines of
evidence indicate that TW10 is the most important target
determining the viral load set point: TW10 is the earliest target
during primary infection [32]; and among all the described HLA-
associated mutations, T242N is the earliest escape mutation that
emerges during acute infections [13]. In light of these previously
reported data and the nature of the CRF01_AE sequence, it would
be interesting to determine whether TW10 is sufficient to protect
B*57/*5801-positive subjects from disease progression. Unfortu-
nately, we saw no clear protective effect of B*57/*5801 in the
cohort reported here. However, as shown by the low median
CD4
+ T-cell count, our cohort was substantially advanced in terms
of disease progression. Therefore, the accumulated compensatory
mutations might have masked the true protective effect of B*57/
*5801. Supporting this explanation, we observed substantially
lower plasma viral loads in the B*57/*5801-positive subjects with
T242N but without the compensatory mutations (p=0.012 by
ANOVA; Figure 4).
We have also shown that the transmission of virus crippled by
T242N might be associated with lower plasma viral loads in HLA-
unmatched recipients, supporting a previous study of clade C
infections [34]. However, the long-term effects of the transmission
of virus attenuated by CTL escape mutations remain unknown
and these contact cases should be examined longitudinally to
determine whether virological escape accompanies the reversion of
the T242N escape mutation.
Limitations
One of the limitations of this study is that we had no
information regarding the timing of HIV transmission within the
couples, although the rate of mutation is known to depend on the
time from transmission [35]. However, perhaps because the
duration of marriage in our discordant couples was quite long
(median of seven years), we detected negligible amino acid changes
between the first and second samplings. Therefore, we believe that
most of the associations between amino acid mutations and HLA
alleles observed in this study occurred in chronic infections.
Another limitation is that this type of analysis depends heavily on
statistical power. Therefore, it is difficult to identify HLA-
associated variations if the allele frequencies and rates of mutation
are low. Moreover, we did not use multiple testing corrections
because of the small sample size, so we must admit there would
have been a substantial number of false positive results. However,
the high odds ratios of some of the novel HLA-associated
mutations in the context of CRF01_AE infections in this Asian
population strongly encourage us to obtain more information
about CTL epitopes in different geographical regions where
distinct HIV clades circulating, to develop globally effective CTL-
based vaccines.
Our contact cases were not incident cases. Inevitably, there is
also concern that the estimated direction of viral transmission was
not true. However, because the HIV epidemic in Thailand started
with commercial sex workers transmitting to their male clients and
then from husbands to their wives [16], and partly because our
study was conducted in a hospital close to a rural community, our
interviews clearly indicated which spouse displayed risk behavior
for HIV infection in most couples.
In conclusion, our data suggest two points: (a) HLA-associated
amino acid mutations and CTL selection pressure on the p24
antigen appear to have the most significant impact on HIV
replication in this CRF01_AE infection in an Asian population;
and (b) the rates of accumulation of CTL escape mutations at the
population level differ substantially between escape mutations,
because the reversion rates varied considerably among the HLA-
associated mutations.
Figure 4. Lower plasma viral loads in B*57/*5801-positive
subjects with T242N. Plasma viral loads of patients grouped by the
presence or absence of B*57/*5801 with T242N with or without the
compensatory H219 and M228 mutations.
doi:10.1371/journal.pone.0011179.g004
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Figure S1 The inserted box magnifies the phylogenetic tree to
show how the couples were identified.
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